Use of the RenalGuard system to prevent contrast-induced AKI

A meta-analysis

Stephanie Mattathil, Saad Ghumman, Jonathan Weinerman, Anand Prasad

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Contrast-induced kidney injury (CI-AKI) following cardiovascular interventions results in increased morbidity and mortality. RenalGuard (RG) is a novel, closed loop system which balances volume administration with forced diuresis to maintain a high urine output. We performed a meta-analysis of the existing data comparing use of RG to conventional volume expansion. Methods: Ten studies were found eligible, of which four were randomized controlled trials. Of an aggregate sample size (N) of 1585 patients, 698 were enrolled in the four RCTs and 887 belonged to the remaining registries included in this meta-analysis. Primary outcomes included CI-AKI incidence and relative risk. Mortality, dialysis, and major adverse cardiovascular events (MACCE) were secondary outcomes. A random effects model was used and data were evaluated for publication bias. Results: RG was associated with significant risk reduction in CI-AKI compared to control (RR: 0.30, 95%CI: 0.18-0.50, P < 0.01). CI-AKI in RG was found to be 7.7% versus 23.6% in the control group (P < 0.01). Use of RG was associated with decreased mortality (RR: 0.43, 95%CI: 0.18-0.99, P = 0.05), dialysis (RR: 0.20, 95%CI: 0.06-0.61, P = 0.01), and MACCE (RR: 0.42, 95%CI: 0.27-0.65, P < 0.01) compared to control. Conclusions: RG significantly reduces rates of CI-AKI compared to standard volume expansion and is also associated with decreased rates of death, dialysis, and MACCE.

Original languageEnglish (US)
Pages (from-to)480-487
Number of pages8
JournalJournal of Interventional Cardiology
Volume30
Issue number5
DOIs
StatePublished - Oct 1 2017

Fingerprint

Meta-Analysis
Dialysis
Mortality
Publication Bias
Diuresis
Risk Reduction Behavior
Sample Size
Registries
Randomized Controlled Trials
Urine
Morbidity
Kidney
Control Groups
Incidence
Wounds and Injuries

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Use of the RenalGuard system to prevent contrast-induced AKI : A meta-analysis. / Mattathil, Stephanie; Ghumman, Saad; Weinerman, Jonathan; Prasad, Anand.

In: Journal of Interventional Cardiology, Vol. 30, No. 5, 01.10.2017, p. 480-487.

Research output: Contribution to journalArticle

Mattathil, Stephanie ; Ghumman, Saad ; Weinerman, Jonathan ; Prasad, Anand. / Use of the RenalGuard system to prevent contrast-induced AKI : A meta-analysis. In: Journal of Interventional Cardiology. 2017 ; Vol. 30, No. 5. pp. 480-487.
@article{57f012eb32904df28f08e53c947ffcf1,
title = "Use of the RenalGuard system to prevent contrast-induced AKI: A meta-analysis",
abstract = "Background: Contrast-induced kidney injury (CI-AKI) following cardiovascular interventions results in increased morbidity and mortality. RenalGuard (RG) is a novel, closed loop system which balances volume administration with forced diuresis to maintain a high urine output. We performed a meta-analysis of the existing data comparing use of RG to conventional volume expansion. Methods: Ten studies were found eligible, of which four were randomized controlled trials. Of an aggregate sample size (N) of 1585 patients, 698 were enrolled in the four RCTs and 887 belonged to the remaining registries included in this meta-analysis. Primary outcomes included CI-AKI incidence and relative risk. Mortality, dialysis, and major adverse cardiovascular events (MACCE) were secondary outcomes. A random effects model was used and data were evaluated for publication bias. Results: RG was associated with significant risk reduction in CI-AKI compared to control (RR: 0.30, 95{\%}CI: 0.18-0.50, P < 0.01). CI-AKI in RG was found to be 7.7{\%} versus 23.6{\%} in the control group (P < 0.01). Use of RG was associated with decreased mortality (RR: 0.43, 95{\%}CI: 0.18-0.99, P = 0.05), dialysis (RR: 0.20, 95{\%}CI: 0.06-0.61, P = 0.01), and MACCE (RR: 0.42, 95{\%}CI: 0.27-0.65, P < 0.01) compared to control. Conclusions: RG significantly reduces rates of CI-AKI compared to standard volume expansion and is also associated with decreased rates of death, dialysis, and MACCE.",
author = "Stephanie Mattathil and Saad Ghumman and Jonathan Weinerman and Anand Prasad",
year = "2017",
month = "10",
day = "1",
doi = "10.1111/joic.12417",
language = "English (US)",
volume = "30",
pages = "480--487",
journal = "Journal of Interventional Cardiology",
issn = "0896-4327",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Use of the RenalGuard system to prevent contrast-induced AKI

T2 - A meta-analysis

AU - Mattathil, Stephanie

AU - Ghumman, Saad

AU - Weinerman, Jonathan

AU - Prasad, Anand

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: Contrast-induced kidney injury (CI-AKI) following cardiovascular interventions results in increased morbidity and mortality. RenalGuard (RG) is a novel, closed loop system which balances volume administration with forced diuresis to maintain a high urine output. We performed a meta-analysis of the existing data comparing use of RG to conventional volume expansion. Methods: Ten studies were found eligible, of which four were randomized controlled trials. Of an aggregate sample size (N) of 1585 patients, 698 were enrolled in the four RCTs and 887 belonged to the remaining registries included in this meta-analysis. Primary outcomes included CI-AKI incidence and relative risk. Mortality, dialysis, and major adverse cardiovascular events (MACCE) were secondary outcomes. A random effects model was used and data were evaluated for publication bias. Results: RG was associated with significant risk reduction in CI-AKI compared to control (RR: 0.30, 95%CI: 0.18-0.50, P < 0.01). CI-AKI in RG was found to be 7.7% versus 23.6% in the control group (P < 0.01). Use of RG was associated with decreased mortality (RR: 0.43, 95%CI: 0.18-0.99, P = 0.05), dialysis (RR: 0.20, 95%CI: 0.06-0.61, P = 0.01), and MACCE (RR: 0.42, 95%CI: 0.27-0.65, P < 0.01) compared to control. Conclusions: RG significantly reduces rates of CI-AKI compared to standard volume expansion and is also associated with decreased rates of death, dialysis, and MACCE.

AB - Background: Contrast-induced kidney injury (CI-AKI) following cardiovascular interventions results in increased morbidity and mortality. RenalGuard (RG) is a novel, closed loop system which balances volume administration with forced diuresis to maintain a high urine output. We performed a meta-analysis of the existing data comparing use of RG to conventional volume expansion. Methods: Ten studies were found eligible, of which four were randomized controlled trials. Of an aggregate sample size (N) of 1585 patients, 698 were enrolled in the four RCTs and 887 belonged to the remaining registries included in this meta-analysis. Primary outcomes included CI-AKI incidence and relative risk. Mortality, dialysis, and major adverse cardiovascular events (MACCE) were secondary outcomes. A random effects model was used and data were evaluated for publication bias. Results: RG was associated with significant risk reduction in CI-AKI compared to control (RR: 0.30, 95%CI: 0.18-0.50, P < 0.01). CI-AKI in RG was found to be 7.7% versus 23.6% in the control group (P < 0.01). Use of RG was associated with decreased mortality (RR: 0.43, 95%CI: 0.18-0.99, P = 0.05), dialysis (RR: 0.20, 95%CI: 0.06-0.61, P = 0.01), and MACCE (RR: 0.42, 95%CI: 0.27-0.65, P < 0.01) compared to control. Conclusions: RG significantly reduces rates of CI-AKI compared to standard volume expansion and is also associated with decreased rates of death, dialysis, and MACCE.

UR - http://www.scopus.com/inward/record.url?scp=85030265898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030265898&partnerID=8YFLogxK

U2 - 10.1111/joic.12417

DO - 10.1111/joic.12417

M3 - Article

VL - 30

SP - 480

EP - 487

JO - Journal of Interventional Cardiology

JF - Journal of Interventional Cardiology

SN - 0896-4327

IS - 5

ER -